Condensed Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (3,599,510)	$ (2,946,257)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	69,983	131,653
Amortization	1,245	1,413
Amortization of right-of-use assets	152,664	75,635
Provision for bad debts	1,000	0
Inventory reserve write-off	1,240	300
Share-based compensation expense	77,585	56,954
Amortization of debt issuance costs and discount	258,802	0
Changes in operating assets and liabilities:
Accounts receivable	(22,623)	(46,485)
Inventory	(305,419)	(64,318)
Prepaid and other assets	(187,359)	150,654
Accounts payable	(137,753)	3,016
Accrued expenses	(792,239)	78,703
Lease liabilities	(44,745)	(91,211)
Other liabilities	(40,995)	2,306
Net cash used in operating activities	(4,568,124)	(2,647,637)
Cash flows from investing activities:
Acquisition of patents	(25,603)	0
Purchases of property and equipment	(64,557)	(8,901)
Net cash used in investing activities	(90,160)	(8,901)
Cash flows from financing activities:
Proceeds from at-the-market sales of common stock	802,242	3,373	$ 8,700,000
Issuance costs for at-the-market sales of common stock	(24,067)	0
Repayment of note payable	0	(141,298)
Payments under lease obligations	0	(6,135)
Net cash provided by (used in) financing activities	778,175	(144,060)
Net change in cash and cash equivalents	(3,880,109)	(2,800,598)
Cash and cash equivalents:
Beginning of period	21,716,077	12,961,936
End of period	17,835,968	10,161,338	$ 17,835,968
Cash paid for:
Interest	0	1,672
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued expense	108,304	12,990
Acquisition of patents included in accounts payable	8,757
Commissions costs relating to certain proceeds from issuance of common stock	0	109
Deferred offering costs reclassified to additional paid-in-capital	$ 1,245	$ 0